Last edition
News about "Dravet syndrome"
Biogen and Stoke Therapeutics to Develop and Commercialize Zorevunersen
Zorevunersen is an investigational antisense oligonucleotide (ASO) that targets the SCN1A gene, the underlying cause of most cases of Dravet syndrome.
Dravet Syndrome | 20/02/2025 | By Aishwarya
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members